A case of aggressive neuroendocrine carcinoma of the stomach

Gastric Cancer

Volumn 6, Issue 1, 2003, Pages 55-59

  Hosoya, Yoshinori ^a   Nagai, Hideo ^a   Koinuma, Koji ^a   Yasuda, Yoshikazu ^a   Kaneko, Yoshinari ^a   Saito, Ken ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Chemotherapy; Loss of heterozygosity; Neuroendocrine carcinoma; Stomach

Indexed keywords

CHROMOGRANIN A; CISPLATIN; ETOPOSIDE; FLUOROURACIL; SYNAPTOPHYSIN;

ADULT; ADVANCED CANCER; ARTICLE; BARIUM MEAL; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER RECURRENCE; CASE REPORT; CHROMOSOME 11Q13; CLINICAL FEATURE; COLON RESECTION; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; DISEASE COURSE; DISSEMINATED CANCER; ENDOCRINE FUNCTION TEST; FOLLOW UP; GASTROSCOPY; GENE; GENE LOCUS; GENE MUTATION; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; JAPAN; LIVER; LOBECTOMY; MALE; MEN1 GENE; METASTASIS; MOLECULAR GENETICS; NEUROENDOCRINE TUMOR; OBSTRUCTIVE JAUNDICE; OMENTECTOMY; OMENTUM; PANCREAS; PANCREAS RESECTION; PERCUTANEOUS TRANSHEPATIC DRAINAGE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; SPLENECTOMY; STOMACH CARCINOMA; SURGICAL TECHNIQUE; TOTAL STOMACH RESECTION; TRANSVERSE COLON; TREATMENT INDICATION; TREATMENT OUTCOME; TUMOR CELL; TUMOR LOCALIZATION;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NEUROENDOCRINE; CISPLATIN; ETOPOSIDE; FLUOROURACIL; GASTRECTOMY; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; OMENTUM; PANCREATIC NEOPLASMS; PERITONEAL NEOPLASMS; STOMACH NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0037270212     PISSN: 14363291     EISSN: None     Source Type: Journal    
DOI: 10.1007/s101200300007     Document Type: Article

References (15)

1. Rindi G, Luinetti O, Cornaggia M, Capella C, Solcia E. Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study. Gastroenterology 1993;104:994-1006.
2. Gilligan CJ, Lawton GP, Tang LH, West AB, Modlin IM. Gastric carcinoid tumors: the biology and therapy of an enigmatic and controversial lesion. Am J Gastroenterol 1995;90:338-52.
3. Matsui K, Jin XM, Kitagawa M, Miwa A. Clinicopathologic features of neuroendocrine carcinomas of the stomach: appraisal of small cell and large cell variants. Arch Pathol Lab Med 1998;122:1010-7.
4. Ahlman H, Kolby L, Lundell L, Olbe L, Wangberg B, Granerus G, et al. Clinical management of gastric carcinoid tumors. Digestion 1994;55:77-85.
5. Kaizaki Y, Fujii T, Kawai T, Saito K, Kurihara K, Fukayama M. Gastric neuroendocrine carcinoma associated with chronic atrophic gastritis type A. J Gastroenterol 1997;32:643-9.
6. Hosoya Y, Fujii T, Nagai H, Shibusawa H, Tsukahara M, Kanazawa K. A case of multiple gastric carcinoids associated with multiple endocrine neoplasia type 1 without hypergastrinemia. Gastrointest Endosc 1999;50:692-5.
7. Debelenko LV, Emmert-Buck MR, Zhuang Z, Epshteyn E, Moskaluk CA, Jensen RT, et al. The multiple endocrine neoplasia type I gene locus is involved in the pathogenesis of type II gastric carcinoids. Gastroenterology 1997;113:773-81.
8. Bordi C, Falchetti A, Azzoni C, D'Adda T, Canavese G, Guariglia A, et al. Aggressive forms of gastric neuroendocrine tumors in multiple endocrine neoplasia type I. Am J Surg Pathol 1997;21:1075-82.
9. Rindi G, Bordi C, Rappel S, La Rosa S, Stolte M, Solcia E. Gastric carcinoids and neuroendocrine carcinomas: pathogenesis, pathology, and behavior. World J Surg 1996;20:168-72.
10. Otsuji E, Yamaguchi T, Taniguchi H, Sakakura C, Kishimoto M, Urata Y, et al. Malignant endocrine carcinoma of the stomach. Hepatogastroenterology 2000;47:601-4.
11. Moertel CG, Kvols LK, O'Connell MJ, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991;68:227-32.
12. Ryoo BY, Kang YK, Im YH, Kim YJ, Kim BS, Kim TY, et al. Adjuvant (cisplatin, etoposide, and 5-fluorouracil) chemotherapy after curative resection of gastric adenocarcinomas involving the esophagogastric junction. Am J Clin Oncol 1999;22:253-7.
13. Fujii T, Kawai T, Saito K, Hishima T, Hayashi Y, Imura J, et al. MEN1 gene mutations in sporadic neuroendocrine tumors of foregut derivation. Pathol Int 1999;49:968-73.
14. D'Adda T, Keller G, Bordi C, Hofler H. Loss of heterozygosity in 11q13-14 regions in gastric neuroendocrine tumors not associated with multiple endocrine neoplasia type 1 syndrome. Lab Invest 1999;79:671-7.
15. Han HS, Kim HS, Woo DK, Kim WH, Kim YI. Loss of heterozygosity in gastric neuroendocrine tumor. Anticancer Res 2000;20:2849-54.